Oncology and Hematology - Prova Education

Episodes 1-16 of 106

MinuteCE®
Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025  
0.50 credits 3 episodes
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 credits 3 episodes
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
MinuteCE®
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
MinuteCE®
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
MinuteCE®
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
0.50 program credits
- Lauren A. Byers, MD
0.50 program credits
Mastering the Sequence: CELMoDs Across Treatment Lines
Mastering the Sequence: CELMoDs Across Treatment Lines
MinuteCE®
Mastering the Sequence: CELMoDs Across Treatment Lines
1.00 program credit
- Sagar Lonial, MD, FACP
- Noopur Raje, MD
1.00 program credit
 Real-World Ready: Practical Tips for Community Oncologists
 Real-World Ready: Practical Tips for Community Oncologists
MinuteCE®
 Real-World Ready: Practical Tips for Community Oncologists
1.00 program credit
- Joshua Richter, MD
- Sagar Lonial, MD, FACP
1.00 program credit
Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
MinuteCE®
Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
1.00 program credit
- Joshua Richter, MD
- Sagar Lonial, MD, FACP
1.00 program credit
MinuteCE®
Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma Activity
1.00 credit 10 episodes
- Joshua Richter, MD
- Sagar Lonial, MD, FACP
- Noopur Raje, MD
1.00 credit 10 episodes
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
MinuteCE®
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
1.00 program credit
- Joshua Richter, MD
- Noopur Raje, MD
1.00 program credit
Next-Generation Innovations: The Future of CELMoDs in Myeloma
Next-Generation Innovations: The Future of CELMoDs in Myeloma
MinuteCE®
Next-Generation Innovations: The Future of CELMoDs in Myeloma
1.00 program credit
- Noopur Raje, MD
1.00 program credit
Why CELMoDs Matter in Myeloma
Why CELMoDs Matter in Myeloma
MinuteCE®
Why CELMoDs Matter in Myeloma
1.00 program credit
- Sagar Lonial, MD, FACP
1.00 program credit
Data Dive: Clinical Evidence Behind CELMoDs
Data Dive: Clinical Evidence Behind CELMoDs
MinuteCE®
Data Dive: Clinical Evidence Behind CELMoDs
1.00 program credit
- Sagar Lonial, MD, FACP
1.00 program credit
Safety First: Navigating CELMoD-Associated Toxicities
Safety First: Navigating CELMoD-Associated Toxicities
MinuteCE®
Safety First: Navigating CELMoD-Associated Toxicities
1.00 program credit
- Joshua Richter, MD
- Noopur Raje, MD
1.00 program credit
Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach
Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach
CME/CE
Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach
0.25 credits
- Heather Wakelee, MD, FASCO
0.25 credits
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
MinuteCE®
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
1.00 program credit
- Hussein Tawbi, MD, PhD
- Paolo A. Ascierto, MD
1.00 program credit
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
MinuteCE®
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit

Prev
1
2
3
…
6
7
Next

1/6